Romanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Orange Juice And Sugar Intervention Study

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
Linkul este salvat în clipboard
stareRecrutare
Sponsorii
University of California, Davis
Colaboratori
Touro University, California

Cuvinte cheie

Abstract

The objectives of this proposal are to address the gaps in knowledge regarding the metabolic effects of consuming orange juice, the most frequently consumed fruit juice in this country, compared to sugar-sweetened beverage.

Descriere

Specific Aims: There is considerable epidemiological evidence that demonstrates associations between added sugar/sugar-sweetened beverage consumption and increased risk for or prevalence of chronic diseases such as cardiovascular disease (CVD), type 2 diabetes (T2D), metabolic syndrome, and gout. Especially concerning is recent evidence from National Health and Nutrition Examination Survey III that demonstrates that there is increased risk of CVD mortality with increased intake of added sugar across quintiles (Yang, 2014). Even the US mean added sugar intake, 15% of daily calories, was associated with an 18% increase in risk of CVD mortality over 15 years. The results from the investigator's recently completed study (1R01 HL09133) corroborate these findings (Stanhope, 2015). They demonstrate that supplementing the ad libitum diets of young adults with beverages containing 0, 10, 17.5 or 25% of daily energy requirement (Ereq) as high fructose corn syrup (HFCS) affects lipid/lipoprotein risk factors for CVD in a dose response manner. Specifically, levels of nonHDL-cholesterol(C), LDL-C, apolipoprotein B (apoB), and postprandial triglycerides (TG) increased linearly over a 2-week period with increasing doses of HFCS. Furthermore, even the participants consuming the 10% Ereq dose exhibited increased levels of these risk factors compared to baseline.

These and similar results have helped to lead to reductions in soda consumption in this country, and new dietary guidelines and FDA food labeling requirements to promote reductions in added sugar consumption. However, there are gaps in knowledge about other sugar-containing foods that lead to public confusion concerning healthier options for soda, and impede further progress in implementing public health policies that will promote further reductions in soda consumption. One such food is naturally-sweetened fruit juice. The amount of sugar in fruit juice is comparable to the amount in soda. Because of this, a consumer seeking answers on the internet will find many articles in which experts state or suggest that the effects of consuming fruit juice are as detrimental as or even worse than those of soda. However, in contrast to soda, fruit juice contains micronutrients and bioactives that may promote health. Therefore the consumer can also find numerous articles on the internet where the health benefits of fruit juice and these bioactives are extolled. There are a limited number of clinical dietary intervention studies that have directly compared the metabolic effects of consuming fruit juice and sugar-sweetened beverage, and their results are not conclusive. Thus we will pursue the following Specific Aims:

1. Specific Aim 1: To compare the weight-independent effects of consuming 25%Ereq as orange juice or sugar-sweetened beverages for 4 weeks on risk factors for CVD and other chronic disease in normal weight and overweight men and women.

2. Specific Aim 2: To mechanistically compare the weight-independent effects of consuming 25%Ereq as orange juice or sugar-sweetened beverages on metabolic processes associated with the development of CVD and T2D in normal weight and overweight men and women.

3. Specific Aim 3: To relate the changes assessed under Specific Aims 1 and 2 to the changes in the urinary levels of metabolites and catabolites of the main flavanones in orange juice, hesperetin and naringenin.

Datele

Ultima verificare: 05/31/2020
Primul depus: 04/09/2018
Inscriere estimată trimisă: 05/14/2018
Prima postare: 05/16/2018
Ultima actualizare trimisă: 06/10/2020
Ultima actualizare postată: 06/11/2020
Data actuală de începere a studiului: 05/31/2018
Data estimată de finalizare primară: 03/30/2023
Data estimată de finalizare a studiului: 03/30/2023

Stare sau boală

Cardiovascular Risk Factor
Type2 Diabetes Mellitus
Insulin Sensitivity
Metabolic Syndrome

Intervenție / tratament

Other: Naturally-sweetened orange juice

Other: Sugar-sweetened beverage

Fază

-

Grupuri de brațe

BraţIntervenție / tratament
Experimental: Naturally-sweetened orange juice
Naturally-sweetened orange juice Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
Other: Naturally-sweetened orange juice
Commercially-available ready-to-serve refrigerated orange juice
Active Comparator: Sugar-sweetened beverage
Sugar-sweetened beverage Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
Other: Sugar-sweetened beverage
Sugar-sweetened water flavored with Kool-Aid (TM)

Criterii de eligibilitate

Vârste eligibile pentru studiu 18 Years La 18 Years
Sexe eligibile pentru studiuAll
Acceptă voluntari sănătoșida
Criterii

Inclusion Criteria: men and pre-menopausal women Body mass index: 20-35 kg/m2 Body weight > than 50 kg Self-reported stable body weight during the prior six months

Exclusion Criteria:

Fasting glucose >125 mg/dl Evidence of liver disorder (AST or ALT >200% upper limit of normal range) Evidence of kidney disorder (>2.0 mg/dl creatinine) Evidence of thyroid disorder (out of normal range) Systolic blood pressure consistently over 140 mmHg or diastolic blood pressure over 90 mmHg Triglycerides > 400 mg/dl LDL-C > 160 mg/dl in combination with Chol:HDL > 4 Hemoglobin < 10 g/dL Pregnant or lactating women Current, prior (within 12 months), or anticipated use of any hypolipidemic or anti-diabetic agents.

Use of thyroid, anti-hypertensive, anti-depressant, weight loss medications or any other medication which, in the opinion of the investigator, may confound study results Use of tobacco Strenuous exerciser (>3.5 hours/week at a level more vigorous than walking) Surgery for weight loss Diet exclusions: Food allergies, special dietary restrictions, routine consumption of less than 3 meals/day, routine ingestion of more than 2 sugar-sweetened beverages or 1 alcoholic beverage/day, unwillingness to consume any food on study menu Veins that are assessed by the R.N.s as being unsuitable for long-term infusions and multiple blood draws from a catheter.

Pre-existing claustrophobia or metal implants that preclude magnetic resonance imaging Any other condition that, in the opinion of the investigators, would put the subject at risk

-

Rezultat

Măsuri de rezultate primare

1. Low density lipoprotein cholesterol (LDL-C) [4 weeks]

Plasma LDL-C concentration

2. Apolipoprotein B (apoB) [4 weeks]

Plasma apoB concentration

3. Uric acid [4 weeks]

Plasma uric acid concentration

4. de novo lipogenesis (DNL) [4 weeks]

%Fractional rate DNL

5. Hepatic triglyceride [4 weeks]

%hepatic triglyceride

6. Endogenous glucose production [4 weeks]

Endogenous glucose production during hyperinsulinemic clamp

Măsuri de rezultate secundare

1. Postprandial triglyceride [4 weeks]

Plasma postprandial triglyceride concentration

2. 3-(3'-hydroxy-4'-methoxyphenyl)hydracrylic [4 weeks]

Urine concentration of 3-(3'-hydroxy-4'-methoxyphenyl)hydracrylic

3. hesperetin-3'-O-glucuronide [4 weeks]

Urine concentration hesperetin-3'-O-glucuronide

4. hesperetin-3'-sulfate [4 weeks]

Urine concentration hesperetin-3'-sulfate

5. Apolipoprotein CIII (apoCIII) [4 weeks]

Fasting and postprandial plasma apoCIII concentration

6. non-high density lipoprotein cholesterol (non-HDL-C) [4 weeks]

Plasma non-HDL-C concentration

Alte măsuri de rezultat

1. Gluconeogenesis [4 weeks]

Determined from glucose isotopomer distribution

2. Glycogenolysis [4 weeks]

Endogenous glucose production minus gluconeogenesis

3. Lipolysis [4 weeks]

Determined from glycerol isotopomer distribution

4. Triglyceride production [4 weeks]

Determined from glycerol isotopomer distribution

5. Energy expenditure [4 weeks]

Postprandial energy expenditure

6. Fat oxidation [4 weeks]

Postprandial fat oxidation

7. Hesperetin-7-O-glucuronide [4 weeks]

Urine concentration hesperetin-7-O-glucuronide

8. Naringenin-4'-O-glucuronide [4 weeks]

Urine concentration naringenin-4'-O-glucuronide

9. Naringen-7-O-glucuronide [4 weeks]

Urine concentration naringen-7-O-glucuronide

10. Fecal microbiota [4 weeks]

Fecal relative bacterial abundance

11. Insulin [4 week]

fasting and postprandial plasma insulin concentration

12. glucose [glucose]

fasting and postprandial plasma glucose concentration

13. Apolipoprotein E (apoE) [4 weeks]

plasma apoE concentration

14. high sensitivity C reactive protein (CRP) [4 weeks]

plasma CRP concentration

15. aspartate aminotransferase (AST) [4 weeks]

plasma AST concentration

16. alanine aminotransferase (ALT) [4 weeks]

plasma ALT concentration

17. gamma-glutamyl transferase (GGT) [4 weeks]

plasma GGT concentration

18. oxidized LDL (oxLDL) [4 weeks]

plasma oxLDL concentration

19. malondialdehyde [4 weeks]

fasting and postprandial plasma malondialdehyde concentration

20. total antioxidant status [4 weeks]

fasting and postprandial plasma total antioxidant status

21. soluble vascular cellular adhesion molecule (sVCAM-1) [4 weeks]

plasma sVCAM-1 concentration

22. monocyte chemotactic protein-1 (MCP-1) [4 weeks]

plasma MCP-1 concentration

23. nitric oxide metabolite (NOx) [4 weeks]

plasma NOx concentration

24. Diastolic and systolic blood pressure [4 weeks]

fasting and postprandial blood pressure

25. Body fat [4 weeks]

%body fat

26. Visceral fat [4 weeks]

Abdominal visceral fat volume

27. Subcutaneous fat [4 weeks]

Abdominal subcutaneous fat volume

28. Physical activity [4 weeks]

Assessed by accelerometer

29. Eating motivation [4 weeks]

Assessed by 19 questions that are scored on a 5-point scale with 5 describing eating behavior driven by reasons other than hunger (i.e. emotions, social pressure)

Alăturați-vă paginii
noastre de facebook

Cea mai completă bază de date cu plante medicinale susținută de știință

  • Funcționează în 55 de limbi
  • Cure pe bază de plante susținute de știință
  • Recunoașterea ierburilor după imagine
  • Harta GPS interactivă - etichetați ierburile în locație (în curând)
  • Citiți publicațiile științifice legate de căutarea dvs.
  • Căutați plante medicinale după efectele lor
  • Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele

Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate

Google Play badgeApp Store badge